InvestSMART

ImpediMed Limited (ASX:IPD)

ALERT: Price-sensitive ASX Announcement for IPD
Current share price for IPD : $0.006 -0.008 (-57.14%)+
Announcement
Release
4 May 2026 10:55AM
Price at Release
$0.014
Full Release
download
Summary
ImpediMed Limited has announced a transformational equity raising of up to $15.2 million to support growth opportunities in high-value markets such as Breast Cancer Related Lymphoedema (BCRL), Heart Health, and Weight Management. The company aims to achieve operating cash flow breakeven by the second half of FY28, following the deployment of growth capital and cost optimization initiatives. The SOZO® platform, a key product in their portfolio, has been commercially launched for heart health and weight management, with FDA clearance and wide payer coverage already in place. The company is leveraging its existing market presence, particularly in the U.S. cancer centers, to expand into new health segments, supported by clinical and regulatory endorsements.
Key Points
  • Equity raising of up to $15.2 million via placement and SPP.
  • Targeting operating cash flow breakeven by H2 FY28.
  • SOZO® platform launched for heart health and weight management.
  • High-value market focus: BCRL, Heart Health, Weight Management.
  • Significant cost savings and debt prepayment initiatives.
  • FDA clearance and strong payer coverage for SOZO® platform.
  • Expansion strategy leveraging existing presence in U.S. cancer centers.
  • Pro forma net cash position of $5.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.